Clinical TrialOct 19, 2026, 09:11 AM
Veradermics' VDPHL01 Phase 3 Trial Meets All Endpoints for Hair Loss
AI Summary
Veradermics, Inc. announced positive topline data from its Phase 3 clinical trial, Study '304', evaluating VDPHL01 for male pattern hair loss. The study met all primary and secondary endpoints with high statistical significance, demonstrating superior hair growth and patient-reported improvements compared to placebo. VDPHL01 also showed a rapid onset of activity and a generally well-tolerated safety profile. These results support the potential for VDPHL01 to become the first FDA-approved non-hormonal oral treatment for pattern hair loss.
Key Highlights
- Veradermics' VDPHL01 Phase 3 Study '304' met all primary and secondary endpoints for mild-to-moderate pattern hair loss in males.
- VDPHL01 showed superior hair growth vs. placebo with average increases of 28.6 hairs/cm² (QD) and 36.4 hairs/cm² (BID) at Month 6.
- 78.8% (QD) and 85.0% (BID) of patients reported improvement in hair coverage on AAIRS vs. 35.3% for placebo.
- Statistically significant separation from placebo on TAHC, PRO, and IGA observed as early as Month 2.
- VDPHL01 demonstrated a favorable safety profile, consistent with Study '302', with no treatment-related SAEs or cardiac AESIs.
- Hypertrichosis was the only TEAE occurring in >5% of patients with an imbalance (2.2% QD, 9.0% BID).
Price Impact
More from MANE
More in Clinical Trial